Overview
Italy healthcare provider's FY2025 revenue rose 3.5% yr/yr
Adjusted EBITDA for FY2025 grew 2.7%
Outlook
Company expects to benefit from growing healthcare demand and aims to strengthen best-in-class positioning
Result Drivers
OUT-OF-REGION PATIENTS - Revenue growth benefited from increased services to out-of-region patients
ACQUISITIONS - Full-year contributions from Sanatorio Triestino and Gruppo Aurelia acquisitions supported revenue
HIGHER ENERGY AND INSURANCE COSTS - Adjusted EBITDA was negatively impacted by higher energy costs at Terme del Friuli-Venezia Giulia
Company press release:
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Beat
EUR 487.10 mln
EUR 480.80 mln (1 Analyst)
FY Net Income
EUR 23.60 mln
FY Adjusted EBITDA
EUR 80.7 mln
Analyst Coverage
The one available analyst rating on the shares is "strong buy"
The average consensus recommendation for the healthcare facilities & services peer group is "buy."
Wall Street's median 12-month price target for Garofalo Health Care SpA is €6.60, about 25.7% above its March 13 closing price of €5.25
The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 17 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .